BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36089502)

  • 21. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis.
    Lough T; Luo Q; Luxmanan C; Anderson A; Suttie J; O'Sullivan P; Darling D
    BMC Urol; 2018 Mar; 18(1):18. PubMed ID: 29523118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of Serum N-glycan Profiling as a Diagnostic Biomarker in Urothelial Carcinoma.
    Oikawa M; Hatakeyama S; Yoneyma T; Tobisawa Y; Narita T; Yamamoto H; Hashimoto Y; Koie T; Narita S; Sasaki A; Tsuchiya N; Habuchi T; Takahashi I; Nakaji S; Ohyama C
    Eur Urol Focus; 2018 Apr; 4(3):405-411. PubMed ID: 28753809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
    Salari K; Sundi D; Lee JJ; Wu S; Wu CL; DiFiore G; Yan QR; Pienkny A; Lee CK; Oberlin D; Barme G; Piser J; Kahn R; Collins E; Phillips KG; Caruso VM; Goudarzi M; Garcia-Ransom M; Lentz PS; Evans-Holm ME; MacBride AR; Fischer DS; Haddadzadeh IJ; Mazzarella BC; Gray JW; Koppie TM; Bicocca VT; Levin TG; Lotan Y; Feldman AS
    Clin Cancer Res; 2023 Sep; 29(18):3668-3680. PubMed ID: 37439796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
    Raman JD; Kavalieris L; Konety B; Porten S; Daneshmand S; Lotan Y; Loo R
    J Urol; 2021 Dec; 206(6):1380-1389. PubMed ID: 34348469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Microscopic Hematuria Guidelines as Applied in 1018 Patients With Microscopic Hematuria.
    Sancı A; Oktar A; Gokce MI; Süer E; Gülpinar O; Gögüs C; Baltacı S; Turkolmez K
    Urology; 2021 Aug; 154():28-32. PubMed ID: 33971192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System.
    Gold SA; Kenigsberg AP; Lotan Y
    J Urol; 2022 Jan; 207(1):52-60. PubMed ID: 34428924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Genomic Urine Assay for Surveillance of Patients with Bladder Cancer Treated with Radiotherapy.
    de Jong FC; Iflé IG; van der Made AC; Kooper D; de Jong JJ; Franckena M; Zuiverloon TCM; van Criekinge W; Incrocci L; Zwarthoff EC; Boormans JL
    Eur Urol Open Sci; 2024 Apr; 62():131-139. PubMed ID: 38496820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of molecular analyses in voided urine for the assessment of patients with hematuria.
    Beukers W; Kandimalla R; van Houwelingen D; Kovacic H; Chin JF; Lingsma HF; Dyrskjot L; Zwarthoff EC
    PLoS One; 2013; 8(10):e77657. PubMed ID: 24143252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Sensitive Urine DNA-Based PENK Methylation Test for Detecting Bladder Cancer in Patients with Hematuria.
    Oh TJ; Lee JY; Seo Y; Woo MA; Lim JS; Na YG; Song KH; Bang BR; Lee JJ; Shin JH; An S
    J Mol Diagn; 2023 Sep; 25(9):646-654. PubMed ID: 37330048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria.
    Karnes RJ; Fernandez CA; Shuber AP
    Mayo Clin Proc; 2012 Sep; 87(9):835-42. PubMed ID: 22883743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria.
    Sagnak L; Ersoy H; Gucuk O; Ozok U; Topaloglu H
    Urol Int; 2011; 87(1):35-41. PubMed ID: 21654152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of patients with microscopic hematuria who are at greater risk for the presence of bladder tumors using a dedicated questionnaire and point of care urine test--a study by the members of Association of Urooncology, Turkey.
    Turkeri L; Mangir N; Gunlusoy B; Yildirim A; Baltaci S; Kaplan M; Bozlu M; Mungan A
    Asian Pac J Cancer Prev; 2014; 15(15):6283-6. PubMed ID: 25124612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.
    Konety B; Shore N; Kader AK; Porten S; Daneshmand S; Lough T; Lotan Y
    Eur Urol; 2019 Aug; 76(2):238-243. PubMed ID: 31103391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Prevalence and Risk Stratification in Adults Presenting With Hematuria: A Population-Based Cohort Study.
    Takeuchi M; McDonald JS; Takahashi N; Frank I; Thompson RH; King BF; Kawashima A
    Mayo Clin Proc Innov Qual Outcomes; 2021 Apr; 5(2):308-319. PubMed ID: 33997630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
    O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
    J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
    Shkolyar E; Zhao Q; Mach KE; Teslovich NC; Lee TJ; Cox S; Skinner EC; Lu Y; Liao JC
    Urol Oncol; 2021 Aug; 39(8):497.e9-497.e15. PubMed ID: 33766467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic tests in urology: urine cytology.
    Lavallée LT; Fergusson D; Dahm P; Scales CD; Witiuk K; Breau RH
    BJU Int; 2012 Dec; 110(11 Pt C):E789-91. PubMed ID: 23106855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.